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Background: Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety
and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and adolescent
asthma patients.
Methods: Fourteen clinical studies (six Phase II and eight Phase III) were conducted as part of the fluticasone furoate
global clinical development programme in asthma. Safety data from 10 parallel-group, randomised, double-blind Phase
II and III studies (including 3345 patients who received at least one dose of fluticasone furoate) were integrated to
provide information on adverse events, withdrawals, laboratory assessments, vital signs and hypothalamic-pituitary-
adrenal axis function. The efficacy of once-daily fluticasone furoate was evaluated in all included studies.
Results: Once-daily fluticasone furoate 100 μg and 200 μg safety profiles were consistent with those reported for other
inhaled corticosteroids, and both doses consistently demonstrated efficacy versus placebo. In the integrated analysis,
no dose-response relationship was observed for the overall incidence of adverse events and there were no significant
effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function.
Conclusion: Once-daily fluticasone furoate 100 μg and 200 μg had acceptable safety profiles and was efficacious in
adult and adolescent patients with asthma. There was no evidence of cortisol suppression at studied doses.
Trial registrations: GSK (NCT01499446/FFA20001, NCT00398645/FFA106783, NCT00766090/112202, NCT00603746/
FFA109684, NCT00603278/FFA109685, NCT00603382/FFA109687, NCT01436071/115283, NCT01436110/115285,
NCT01159912/112059, NCT01431950/114496, NCT01165138/HZA106827, NCT01086384/106837, NCT01134042/
HZA106829 and NCT01244984/1139879).
Keywords: Adverse events, Cortisol suppression, Fluticasone furoate, Forced expiratory volume in one second, Inhaled
corticosteroid, Integrated analysis, SafetyBackground
Inhaled corticosteroids (ICS) are the mainstay of treat-
ment for all severities of persistent asthma, leading to
improved symptom control, improved lung function and
quality of life, and reduced asthma mortality [1]. Never-
theless, poorly controlled asthma remains prevalent [2],* Correspondence: obyrnep@mcmaster.ca
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Most ICS are administered twice daily; however, improved
compliance with once-daily regimens has been demon-
strated in mild-to-moderate asthma [3]. A case-control
study using the UK General Practice Research Database
reported better adherence and reduced costs for patients
with asthma who switched to once-daily ICS from twice-
daily ICS [4].
The tolerability profile of ICS for asthma treatment is
well established. Localised effects, e.g., dysphonia and
oral candidiasis, have been reported [1], and prolonged
high-dose ICS usage has been associated with adrenalle is distributed under the terms of the Creative Commons Attribution 4.0
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new ICS it is important to assess the safety profile, includ-
ing potential systemic effects, e.g., cortisol supression.
The ICS fluticasone furoate (FF), administered using
the ELLIPTA® dry powder inhaler, is a once-daily main-
tenance treatment for adult and adolescent (≥12 years)
patients with asthma. FF has higher cellular accumula-
tion and slower efflux compared with other corticoste-
roids [5], resulting in enhanced lung residency and 24-h
efficacy in patients with asthma [6–8]. FF 100 μg or
200 μg is approved as monotherapy in a number of
countries, including the USA [9], and in combination with
vilanterol, a novel long-acting beta2 agonist, as asthma
maintenance therapy in multiple countries, including the
USA and in the EU [10–12].
An integrated safety analysis and overview of efficacy
data from Phase II and III studies, which assessed the
overall benefit and risks of once-daily FF 100 μg or 200 μg
for patients with varying severities of persistent asthma,
was carried out using all available data.Methods
Clinical studies
Fourteen clinical studies (six Phase II and eight Phase III)
were conducted (FF asthma global clinical development
programme): 10 assessed FF only and four investigated
FF/vilanterol with a FF arm (Table 1 [13–26]). In 12 stud-
ies, FF was administered using the ELLIPTA® dry powder
inhaler in the evening. The remaining studies used Rota-
disk Diskhaler™ [13] or Diskus™/Accuhaler™ [14], in the
morning or evening.
Across the 14 studies, inclusion criteria were as follows:
patients ≥12 years of age; a clinical history of asthma (in
accordance with the definition of National Institutes of
Health [27]); forced expiratory volume in one second
(FEV1), 40–90% of the predicted normal value (50–90% in
one study [24]); bronchodilator reversibility of disease
(≥12% and ≥200 mL increase in FEV1 within 10–40 min
following two to four inhalations of albuterol/salbutamol);
and documented use of albuterol/salbutamol and/or
asthma symptoms on ≥4 of the last 7 consecutive days of
a run-in period (or in one study, ≥3 of the last 7 consecu-
tive days of the run-in period [24]). As patients entering
the Phase III studies were symptomatic on ICS or ICS/
LABA therapy, their asthma severity may be considered
equivalent to GINA steps 3–4 [1].
All studies complied with the principles of Good Clin-
ical Practice [28] and were approved by relevant Ethics
Committees/Institutional Review Boards. Written informed
consent was obtained. Studies were conducted in ac-
cordance with the applicable version of the Declaration
of Helsinki [29]. Regulatory approval was obtained from
the relevant health authority where required.Safety analysis
Key comparisons of interest for integrated safety analyses
were FF 100 μg versus placebo and FF 200 μg versus pla-
cebo. Data from 10 completed Phase II and III parallel-
group, double-blind studies, in which FF was delivered via
the ELLIPTA® inhaler, were integrated to assess FF safety
(Table 1). The four additional studies provided further
supporting safety data for FF [13–15, 26]; however, these
were reviewed individually and not integrated as they had
either a different design (e.g., crossover/open-label) or did
not use the ELLIPTA® inhaler. The treatment groups ana-
lysed were as follows: once-daily FF 50 μg, 100 μg and
200 μg; twice-daily fluticasone propionate (FP) 100 μg,
250 μg and 500 μg; and placebo. All randomised patients
who received at least one dose of study medication were
included in the integrated analysis. As the data were inte-
grated to support the regulatory filings of FF monotherapy
for the treatment of asthma, the cut-off for this analysis
was 15 February 2013; data from studies reported follow-
ing this date were not included.
The integrated analysis determined (a) the rate of ad-
verse events (AEs) and (b) the exposure-adjusted AE rate
(to account for variation in treatment exposure across
the groups) reported as the number of patients with an
event per 1000 patient-years of exposure.
AEs were coded and grouped by System Organ Class
and Preferred Term using the Medical Dictionary for
Regulatory Activities (MedDRA, version 15.1). AEs of
special interest (AESI) were defined using pre-selected
MedDRA preferred terms and based on the known AE
profile/pharmacology of corticosteroids: hypersensitivity,
bone disorders, local steroid effects (e.g., oral candidiasis/
hoarseness), ocular effects, glucose effects, pneumonia, lower
respiratory tract infection and systemic effects (e.g.,
hypothalamic-pituitary-adrenal [HPA] axis). A severe
asthma exacerbation was defined as an asthma deterior-
ation requiring the use of systemic or oral corticosteroids
for ≥3 days, or an in-patient hospitalisation or emergency
department visit due to asthma that required systemic
corticosteroids (asthma exacerbations were only recorded
as AEs if they met the definition of a serious AE). Vital
signs (diastolic and systolic blood pressure, heart rate) and
laboratory assessments (clinical chemistry and haematol-
ogy parameters) were also integrated.
The asthma clinical programme assessed 24-h urine and
serum cortisol excretion. Urinary cortisol measurements
were collected in seven of the 10 studies integrated for
safety. Urinary cortisol excretion was log-transformed and
analysed in the urine cortisol population (a subset of
patients whose urine samples did not have confounding
factors that could affect the interpretation of the results,
e.g., inadequate urine volume, inappropriate collection
time, 24-h creatinine excretion below the lower limit of
threshold, use of prohibited medications or missing the
Table 1 Clinical studies conducted as part of the FF global clinical development programme in asthma
Study Phase Number of
patients
Treatment arms Study duration,
weeks
Primary end-point Additional end-points Included in integrated
safety analysis
Medley et al. [13]a
(NCT01499446)
II dose regimen 575 FF 100 μg OD morning;
FF 100 μg OD evening;
FF 250 μg evening; placebo
4 Mean change from baseline
in daily trough PEF
FEV1, symptom-free days,
rescue-free days, withdrawals,
safety (AEs, 24-h UFC)
No
Woodcock et al. [14]b
(NCT00398645)
II dose regimen 545 FF 200, 400 μg OD morning;
FF 200, 400 μg OD evening;
FF 200 μg BD; placebo
8 Mean change from baseline
in trough FEV1
Safety (AEs, withdrawals, 24-h
UFC)
No
Woodcock et al. [15]c
(NCT00766090)
II dose regimen 190 FF, FP 200 μg OD evening;
FF, FP 100 μg BD; placebo
4 Mean change from baseline
in trough FEV1
Safety (AEs, 24-h UFC) No
Busse et al. [16]c
(NCT00603746)
II dose ranging 627 FF 200, 400, 600, 800 μg OD
evening;
FP 500 μg BD; placebo
8 Mean change from baseline
in trough FEV1
Asthma symptom scores, PEF,
symptom-free days, rescue-free
days, withdrawals, safety (AEs,
24-h UFC)
Yes
Bleecker et al. [17]c
(NCT00603278)
II dose ranging 622 FF 100, 200, 300, 400 μg OD
evening; FP 250 μg BD;
placebo
8 Mean change from baseline
in trough FEV1
PEF, symptom-free and rescue-
free periods, withdrawals, safety
(AEs, 24-h UFC)
Yes
Bateman et al. [18]c
(NCT00603382)
II dose ranging 598 FF 25, 50, 100, 200 μg OD
evening;
FP 100 μg BD; placebo
8 Mean change from baseline
in trough FEV1
PEF, symptom-free and rescue-
free periods, withdrawals, safety
(AEs, 24-h UFC)
Yes
O’Byrne et al. [19]c
(NCT01436071)
III efficacy 248 FF 50 μg OD evening;
placebo
12 Mean change from baseline
in trough FEV1
Rescue-free and symptom-free
24-h periods, PEF, ACT, QoL,
safety (AEs, severe exacerbations)
Yes
Busse et al. [20]c
(NCT01436110)
III efficacy 351 FF 50 μg OD evening;
FP 100 μg BD;
placebo
24 Mean change from baseline
in trough evening FEV1
Rescue-free and symptom-free
24-h periods, PEF, ACT, QoL, safety
(AEs, severe exacerbations)
Yes
Lötvall et al. [21]c
(NCT01159912)
III efficacy 343 FF 100 μg OD evening;
FP 250 μg BD; placebo
24 Mean change from baseline
in trough evening FEV1
Rescue-free and symptom-free
24-h periods, PEF, ACT, QoL,
safety (AEs, severe exacerbations,
24-h UFC)
Yes
Woodcock et al. [22]c
(NCT01431950)
III efficacy 238 FF 100 μg, 200 μg OD evening 24 Mean change from baseline
in trough FEV1
Rescue-free and symptom-free




Bleecker et al. [23]c
(NCT01165138)
III efficacy 609 FF/VI 100/25 μg;
FF 100 μg OD evening;
placebo
12 Mean change from baseline
in trough FEV1 and serial
(0–24 h) weighted mean FEV1
Rescue-free and symptom-free
24-h periods, QoL, withdrawals,
safety (AEs, severe exacerbations,
24-h UFC)
Yes
Bateman et al. [24]c
(NCT01086384)
III efficacy 2019 FF/VI 100/25 μg, FF 100 μg OD
evening
≥24–78 Time to first severe exacerbation Rate of severe exacerbations per













Table 1 Clinical studies conducted as part of the FF global clinical development programme in asthma (Continued)
O’Byrne et al. [25]c
(NCT01134042)
III efficacy 586 FF/VI 200/25 μg OD evening;
FF 200 μg OD evening;
FP 500 μg BD
24 Mean change from baseline
in trough FEV1 and serial
(0–24 h) weighted mean FEV1
Rescue-free 24-h and symptom-
free 24-h periods, QoL, PEF, ACT,
safety (AEs, 24-h UFC)
Yes
Muraki et al. [26]c
(NCT01244984)
III safety 243 FF/VI 100/25 μg, FF/VI
200/25 μg, FF 100 μg
OD evening
52 Safety (AEs, severe exacerbations,
24-h UFC)
PEF, asthma symptom scores No
Clinicaltrials.gov study registration numbers are provided in brackets after each study citation
FF/VI 100/25 μg = 92/22 μg (emitted). FF/VI 200/25 μg = 184/22 μg (emitted). FF 100 μg = 90 μg (emitted). FF 200 μg = 182 μg (emitted)
ACT asthma control testTM, AE adverse event, BD twice daily, FEV1 forced expiratory volume in one second, FF fluticasone furoate, FP fluticasone propionate, OD once daily, PEF peak expiratory flow, QoL quality of life,
UFC urinary free cortisol excretion, VI vilanterol
aFF administered via Rotadisk DiskhalerTM
bFF administered via DiskusTM/AccuhalerTM











O’Byrne et al. Respiratory Research  (2016) 17:157 Page 5 of 11baseline and/or end of treatment assessments). An ana-
lysis of covariance model was used, controlling for the
following baseline effects (log): region, sex, age, treat-
ment and study.
Efficacy analysis
Three strengths of FF monotherapy were assessed as
part of a Phase III programme [19–26]: FF 50 μg, 100 μg
and 200 μg (Table 1). The efficacy of FF 50 μg was not
demonstrated and was not submitted for regulatory ap-
proval. The efficacy assessment mainly used data from in-
dividual studies. Trough (24-h post-dose for once-daily
FF) FEV1, serial 0–24-h weighted mean FEV1 and peak ex-
piratory flow (PEF) were evaluated, as well as symptomatic
end-points (rescue-free and symptom-free 24-h periods)
and Asthma Control Test™ score. To support regulatory
submissions, the only two Phase III studies that were pla-
cebo controlled and included FF 100 μg were integrated.
Access to the datasets supporting the conclusions
of this manuscript may be obtained via https://www.
clinicalstudydatarequest.com/.
Results
A total of 4203 patients in the 10 studies that were inte-
grated for the safety analysis received at least one dose
of study drug (3345 patients received at least one dose
of FF). Treatment exposure varied across treatment
groups from 60.28 to 1179.36 patient-years, with the
greatest exposure reported for the FF 100 μg group
(Additional file 1: Table S1). As a placebo comparator is
not ethical in longer-term studies, a placebo arm was
not included in studies longer than 24 weeks. A total of
537 patients (32%) in the FF 100 μg group were treated
for >52 weeks.
Safety
A summary of the AE incidence and exposure-adjusted
AE incidence for each treatment arm is provided (Table 2).
The most frequently reported AEs for the FF treat-
ment groups in the integrated analysis were headache,Table 2 Summary of the AE profile for the integrated clinical studie




Any AE 278 (32) 121 (36) 912 (55)
Any drug-related AE 22 (3) 8 (2) 103 (6)
Any SAE 7 (<1) 1 (<1) 38 (2)
Any drug-related SAE 0 0 3 (<1)
Any AE leading to
discontinuation of
study drug
8 (<1) 2 (<1) 28 (2)
Deaths 0 0 2 (<1)a
AE adverse event, BD twice daily, FF fluticasone furoate, OD once daily, FP fluticason
aNeither death was determined by the investigator to be related to study medicationasopharyngitis, upper respiratory tract infection, bron-
chitis, oropharyngeal pain and cough (Table 3). There
were no additional findings in the non-integrated studies.
Nasopharyngitis, oropharyngeal pain, sinusitis, influenza,
back pain, dysphonia and viral respiratory tract infection
occurred at a higher rate in patients treated with FF 100 μg
and 200 μg, versus placebo. However, there were generally
no differences in the exposure-adjusted AE rates for FF
100 μg versus placebo, except for back pain and viral re-
spiratory tract infection. Similarly, there were no clear dif-
ferences in exposure-adjusted AE rates between FF and FP.
In two long-term studies (FF 100 μg for >6 months
[24, 26]), there was generally no difference in the pattern
of new AE occurrence after 6 months and no increased
incidence of AEs during the second 6 months, compared
with the first 6 months. For example, in one study of up
to 78 weeks, the AE incidence with an onset in the first
6 months was 54%, compared with 38% with an onset of
after 6 months. There was no pattern to suggest a differ-
ence in the AE profile according to length of study
medication exposure.
The most frequently reported drug-related AEs in the
FF treatment groups were headache, dysphonia and oral/
oropharyngeal candidiasis. The incidence of drug-related
AEs ranged from 2% with FF 50 μg to 6% with FF
100 μg and 200 μg for once-daily administration, and up
to 8% with twice-daily FP 250 μg and FP 500 μg.
Serious AEs (SAEs) were experienced by <1–2% of
patients across the treatment groups (Table 2), most
frequently in the FF 100 μg group (2%, n = 38). Asthma
exacerbation was the most common SAE, experienced
by nine patients in the FF 100 μg group and one patient
in each of the placebo, FF 200 μg and twice-daily FP
500 μg groups. All nine patients with severe asthma ex-
acerbations in the FF 100 μg groups were from a study
that specifically examined exacerbations. That study
was ≤78 weeks in duration (compared with ≤24 weeks
in other studies), had no placebo arm and, unlike other
studies, recruited patients with a history of severe asthma
exacerbations in the previous year [24]. Only four SAEss
OD FF 200 μg OD
(n = 608)
FP 100 μg BD
(n = 217)
FP 250 μg BD
(n = 214)
FP 500 μg BD
(n = 305)
256 (42) 94 (43) 90 (42) 136 (45)
36 (6) 10 (5) 18 (8) 24 (8)
7 (1) 3 (1) 1 (<1) 4 (1)
0 0 0 1 (<1)
10 (2) 4 (2) 4 (2) 6 (2)
0 0 0 0
e propionate, SAE serious adverse event
n
Table 3 Most frequent on-treatment AEs reported with ≥ 3% incidence in any treatment groups (integrated clinical studies)
AE (preferred term), na (%) Placebo
(n = 858)
FF 50 μg OD
(n = 338)
FF 100 μg OD
(n = 1663)
FF 200 μg OD
(n = 608)
FP 100 μg BD
(n = 217)
FP 250 μg BD
(n = 214)
FP 500 μg BD
(n = 305)
Any AE 278 (32) 121 (36) 912 (55) 256 (42) 94 (43) 90 (42) 136 (45)
Headache 66 (8) 29 (9) 228 (14) 44 (7) 24 (11) 15 (7) 25 (8)
Nasopharyngitis 45 (5) 15 (4) 181 (11) 53 (9) 14 (6) 11 (5) 43 (14)
URTI 16 (2) 8 (2) 111 (7) 15 (2) 7 (3) 12 (6) 7 (2)
Bronchitis 15 (2) 0 98 (6) 15 (2) 3 (1) 5 (2) 7 (2)
Oropharyngeal pain 11 (1) 2 (<1) 71 (4) 19 (3) 4 (2) 6 (3) 11 (4)
Cough 9 (1) 3 (<1) 68 (4) 13 (2) 2 (<1) 5 (2) 15 (5)
Pharyngitis 24 (3) 14 (4) 55 (3) 8 (1) 5 (2) 2 (<1) 7 (2)
Sinusitis 8 (<1) 5 (1) 53 (3) 15 (2) 6 (3) 5 (2) 6 (2)
Influenza 9 (1) 5 (1) 45 (3) 17 (3) 6 (3) 0 7 (2)
Back pain 4 (<1) 7 (2) 52 (3) 11 (2) 4 (2) 2 (<1) 4 (1)
Dysphonia 4 (<1) 1 (<1) 23 (1) 11 (2) 3 (1) 6 (3) 6 (2)
Rhinitis 7 (<1) 1 (<1) 27 (2) 7 (1) 3 (1) 0 8 (3)
Viral respiratory tract infection 0 2 (<1) 18 (1) 8 (1) 0 0 8 (3)
Exposure-adjusted incidence rate per 1000 patient-years
AE
(preferred term), n (%)
Placebo FF 50 μg OD FF 100 μg OD FF 200 μg OD FP 100 μg BD FP 250 μg BD FP 500 μg BD
Patient-years 185.6 87.5 1179.4 169.2 61.0 60.3 95.7
Headache 355.6 331.5 193.3 260.1 393.4 248.8 261.2
Nasopharyngitis 242.5 171.5 153.5 313.3 229.5 182.5 449.3
URTI 86.2 91.4 94.1 88.7 114.8 199.1 73.1
Bronchitis 80.8 0 83.1 88.7 49.2 82.9 73.1
Oropharyngeal pain 59.3 22.9 60.2 112.3 65.6 99.5 114.9
Cough 48.5 34.3 57.7 76.9 32.8 82.9 156.7
Pharyngitis 129.3 160.0 46.6 47.3 82.0 33.2 73.1
Sinusitis 43.1 57.2 44.9 88.7 98.4 82.9 62.7
Influenza 48.5 57.2 38.2 100.5 98.4 0 73.1
Back pain 21.6 80.0 44.1 65.0 65.6 33.2 41.8
Dysphonia 21.6 11.4 19.5 65.0 49.2 99.5 62.7
Rhinitis 37.7 11.4 22.9 41.4 49.2 0 83.6
Viral respiratory tract infection 0 22.9 15.3 47.3 0 0 83.6
AE adverse event, BD twice daily, FF fluticasone furoate, FP fluticasone propionate, OD once daily, URTI upper respiratory tract infection
aNumbers represent the number of patients with an event per 1000 patient-years of exposure
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lated: pneumonia, asthma exacerbation and non-cardiac
chest pain with FF 100 μg, and haemoptysis with twice-
daily FP 500 μg. There was no notable difference in the in-
cidence of AEs leading to withdrawal across treatment
groups (0–2%; Table 2); the most frequent of these were
asthma exacerbation, dyspnoea and pneumonia.
Local steroid effects (comprising oropharyngeal pain,
dysphonia, oral candidiasis and oropharyngeal candidia-
sis) were the most frequent AESI; the exposure-adjusted
incidence per 1000 patient-years was 80.8 (placebo),
103.4 (FF 100 μg) and 283.8 (FF 200 μg; Table 4). No
AEs indicative of HPA axis disorders were reported. Thepneumonia incidence was low (≤0.7%) across all groups
(Additional file 2: Figure S1). The exposure-adjusted in-
cidence of pneumonia (Table 4) was similar between FF
100 μg and placebo, and was numerically higher with FF
200 μg (8.5, 10.8 and 23.6, respectively, per 1000 patient-
years); however, the confidence intervals (CIs) were wide
and overlapped across all groups, including placebo
(Additional file 2: Figure S1). Serious pneumonia occurred
at comparable rates for FF 100 μg, FF 200 μg and placebo
(4.2, 5.9 and 5.4, respectively, per 1000 patient-years;
Additional file 3: Figure S2).
Urinary cortisol levels were measured in seven of
the 10 integrated studies (Table 1). At the end of
Table 4 AESI occurring in any treatment groups (integrated clinical studies)
AE of special interest (preferred term), na (%) Placebo
(n = 858)
FF 50 μg OD
(n = 338)
FF 100 μg OD
(n = 1663)
FF 200 μg OD
(n = 608)
FP 100 μg BD
(n = 217)
FP 250 μg BD
(n = 214)
FP 500 μg BD
(n = 305)
Local steroid effects 15 (2) 7 (2) 122 (7) 48 (8) 8 (4) 18 (8) 25 (8)
Oropharyngeal pain 11 (1) 2 (<1) 71 (4) 19 (3) 4 (2) 6 (3) 11 (4)
Dysphonia 4 (<1) 1 (<1) 23 (1) 11 (2) 3 (1) 6 (3) 6 (2)
Oral candidiasis 0 4 (1) 18 (1) 8 (1) 1 (<1) 4 (2) 4 (1)
Oropharyngeal candidiasis 1 (<1) 1 (<1) 7 (<1) 9 (1) 1 (<1) 2 (<1) 6 (2)
LRTI excluding pneumonia 16 (2) 1 (<1) 114 (7) 19 (3) 3 (1) 5 (2) 7 (2)
Bronchitis 15 (2) 0 98 (6) 15 (2) 3 (1) 5 (2) 7 (2)
Hypersensitivityb 13 (2) 3 (<1) 41 (2) 6 (<1) 2 (<1) 2 (<1) 6 (2)
Bone disordersb 0 2 (<1) 21 (1) 2 (<1) 1 (<1) 0 4 (1)
Pneumoniab 2 (<1) 0 10 (<1) 4 (<1) 1 (<1) 0 0
Effects on glucoseb 0 0 11 (<1) 2 (<1) 0 0 0
Ocular effectsb 0 0 6 (<1) 0 0 0 0
Exposure-adjusted incidence rate per 1000 patient-years
AE of special interest (preferred term), n (%) Placebo FF 50 μg OD FF 100 μg OD FF 200 μg OD FP 100 μg BD FP 250 μg BD FP 500 μg BD
Patient-years 185.6 87.5 1179.4 169.2 61.0 60.3 95.7
Local steroid effects 80.8 80.0 103.4 283.8 131.1 298.6 261.2
Oropharyngeal pain 59.3 22.9 60.2 112.3 65.6 99.5 114.9
Dysphonia 21.6 11.4 19.5 65.0 49.2 99.5 62.7
Oral candidiasis 0 45.7 15.3 47.3 16.4 66.4 41.8
Oropharyngeal candidiasis 5.4 11.4 5.9 53.2 16.4 33.2 62.7
LRTI excluding pneumonia 86.2 11.4 96.7 112.3 49.2 82.9 73.1
Bronchitis 80.8 0 83.1 88.7 49.2 82.9 73.1
Hypersensitivityb 70.0 34.3 34.8 35.5 32.8 33.2 62.7
Bone disordersb 0 22.9 17.8 11.8 16.4 0 41.8
Pneumoniab 10.8 0 8.5 23.6 16.4 0 0
Effects on glucoseb 0 0 9.3 11.8 0 0 0
Ocular effectsb 0 0 5.1 0 0 0 0
AE adverse event, BD twice daily, FF fluticasone furoate, FP fluticasone propionate, LRTI lower respiratory tract infection, OD once daily
aNumbers represent the number of patients with an event per 1000 patient-years of exposure
bNo individual event occurred in ≥1% of patients
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were similar to baseline levels and all mean ratios from
treatment end to baseline were close to 1 in the once-
daily FF 100 μg and 200 μg, twice-daily FP 100 μg, 250 μg
and 500 μg, and placebo groups. In the adjusted means
analysis, there were no statistically significant differences
in 24-h urinary cortisol excretion from baseline to treat-
ment end between each FF treatment group and placebo
(Fig. 1); the percentage of patients with a change from
normal urinary cortisol levels at baseline to low levels dur-
ing treatment was similar between the FF (<1%, FF
100 μg, and 3%, FF 200 μg) and placebo (2%) treatment
groups.
Vital sign and laboratory assessments were reviewed
as part of the integrated analysis; no apparent treatment-
related effects were observed.Efficacy in Phase II/III studies
Lung function
Across the Phase II and III studies, FF 100 μg and
200 μg consistently improved trough FEV1, compared
with placebo (Fig. 2). In Phase III studies, the treatment
differences between FF 100 μg and placebo for change
from baseline in trough FEV1 were 146 mL (95% CI: 36–
257 [21]) and 136 mL (95% CI: 51–222 [23]), at 24 weeks
and 12 weeks, respectively. In one study, weighted mean
FEV1 (0–24 h; change from baseline) was measured and
FF 100 μg demonstrated a statistically significant differ-
ence of 186 mL (95% CI: 62–310) from placebo at the
end of the 12-week treatment period [23]. In another
study, the efficacy of once-daily FF 200 μg was similar to
twice-daily FP 500 μg in terms of trough and 0–24-h
weighted mean FEV1 improvement [25]. Finally, in a
Fig. 1 Least squares geometric mean ratio to baseline (95% CI) in
urinary free cortisol excretion at end of treatment (integrated clinical
studies, urine cortisol population). Analysis performed using ANCOVA
with covariates of region, study, gender, age, treatment and the log of
the baseline values. Includes studies NCT00603746, NCT00603278,
NCT00603382, NCT01159912, NCT01431950, NCT01165138 and
NCT01134042 [16–18, 21–23, 25]. Abbreviations: ANCOVA, analysis of
covariance; BD, twice daily; CI, confidence interval; FF, fluticasone
furoate; FP, fluticasone propionate; LS, least squares; OD, once daily
Fig. 2 Forest plots for change from baseline in trough FEV1. (a) FF 100 μg
population). *In study NCT01499446, the final approved inhaler for FF deliv
one second; FF, fluticasone furoate; ITT, intent-to-treat; LS, least squares; OD
O’Byrne et al. Respiratory Research  (2016) 17:157 Page 8 of 11Phase II study, patients with persistent asthma not con-
trolled by short-acting beta2 agonists had significant FEV1
and evening PEF improvements after receiving FF 100 μg
or 200 μg, versus placebo (p ≤0.005 [18]).
Symptomatic end-points
FF 100 μg and 200 μg resulted in improvements in the
proportion of rescue-free 24-h periods versus placebo in
all studies where this was measured (Fig. 3). In the only
two Phase III studies that compared FF with placebo, FF
100 μg demonstrated significant improvements in the
proportion of rescue-free 24-h periods versus placebo
(14.8%, p <0.001 [23], and 8.7%, p = 0.007 [21]).
Exacerbations
Exacerbations were assessed in the integrated safety ana-
lysis. Patients who received FF 100 μg had a 53.4% risk re-
duction for a severe asthma exacerbation by the end of
the treatment period, compared with placebo (hazard ratio
[HR]: 0.466, 95% CI: 0.240–0.906; p = 0.024). Relative to
placebo-treated patients, risk reductions for severe asthma
exacerbations were also seen with FF 200 μg (64.8% risk
reduction; HR: 0.352, 95% CI: 0.171–0.724; p = 0.005).
Discussion
In this integrated analysis, FF had an acceptable safety
profile, comparable with other ICS. The specific effectsversus placebo (ITT population), and (b) FF 200 μg versus placebo (ITT
ery was not used [13]. Abbreviations: FEV1, forced expiratory volume in
, once daily
Fig. 3 Forest plots for change from baseline (95% CI) in percentage of rescue-free 24-h periods. (a) FF 100 μg versus placebo (ITT population),
and (b) FF 200 μg versus placebo (ITT population). Abbreviations: CI, confidence interval; FF, fluticasone furoate; ITT, intent-to-treat; LS, least
squares; OD, once daily
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most frequently reported AEs were as anticipated, hav-
ing been reported with other ICS (upper respiratory
tract infection, bronchitis, oropharyngeal pain and cough
[30]) or commonly experienced by patients with asthma
(headache and nasopharyngitis were reported at similar
frequencies in the placebo group). Despite a dose-response
relationship between ICS use in asthma and oral candidiasis
being well recognised, oral/oropharyngeal candidiasis rates
were low and did not occur in more than 2% of FF- or FP-
treated patients in this integrated analysis. However, the
exposure-adjusted presentation of AESI indicated a higher
incidence of local steroid effects for FF 200 μg, compared
with FF 100 μg and placebo.
Pneumonia was pre-specified as an AESI because it
has been reported as an ICS-related event in chronic ob-
structive pulmonary disease, but no clear association has
been identified with the use of ICS and pneumonia in
asthma [31]. When assessing AEs across multiple studies
of varying lengths and population size, it is important to
consider exposure-adjusted incidence to account for dis-
parities. In this integrated analysis, the incidence of pneu-
monia was low (<1%) in all treatment groups and,
although the exposure-adjusted incidence of pneumonia
was slightly higher with FF 200 μg than FF 100 μg or pla-
cebo, the CIs were wide and overlapped (Additional file 2:
Figure S1). An increased pneumonia incidence with higherdoses cannot be ruled out, but the absolute risk of
pneumonia was small and the exposure-adjusted inci-
dence rates were consistent with the background rate
in the asthmatic population [32] and, for FF 200 μg,
comparable to that calculated for placebo, FP and bude-
sonide in a meta-analysis [31]. There was no evidence
of a higher rate of other AESI (hypersensitivity, bone
disorders, adrenal suppression, ocular effects and effects
on glucose [based on known pharmacological effects of
corticosteroids]), relative to placebo or active comparator.
Beyond the present analysis, the safety profile of FF is
supported by the clinical experience of FF in combination
with vilanterol. Long-term safety evaluation of FF/
vilanterol 100/25 μg and FF/vilanterol 200/25 μg has not
identified any additional potential corticosteroid-related
effects or significant findings from formal ophthalmo-
logical examinations after 52 weeks of exposure [33].
Cortisol suppression has been observed in patients with
asthma who have normal HPA axis function at baseline
receiving high doses of ICS [34]. However, in the studies
included in our analyses there were no reports of signifi-
cant cortisol suppression. In a formal HPA axis study,
measurement of 24-h serum cortisol (a sensitive method
for assessing adrenocortical activity) was used to assess
non-inferiority of FF/vilanterol (100/25 μg and 200/25 μg)
compared with placebo [35]. There were no statistically
significant differences in 0–24-h weighted mean serum
O’Byrne et al. Respiratory Research  (2016) 17:157 Page 10 of 11cortisol between either FF/vilanterol treatment and pla-
cebo after 6 weeks of treatment, but the active control
(7 days of once-daily prednisolone 10 mg) significantly re-
duced serum cortisol levels. In the present study, few pa-
tients in any treatment group experienced below-normal
levels of urinary free cortisol excretion at the end of treat-
ment, and the incidence reported within the FF groups
was similar to that in placebo.
In the efficacy analysis, once-daily FF 100 μg and
200 μg treatment for patients with persistent asthma
produced consistent trough FEV1 improvements and in-
creases in the proportion of rescue-free 24-h periods,
compared with placebo. This present analysis examined
evening dosing (primarily), but a subsequent study has
suggested that morning and evening FF doses are equally
efficacious as assessed by improvement from baseline in
FEV1 versus placebo [36].
Consistent with previous results [37], the data pre-
sented here suggest that FF has a wide therapeutic index;
the therapeutic dose range was efficacious across indi-
vidual studies, with a tolerability profile as expected for
the class and no evidence of cortisol suppression at the
doses assessed.
The strengths of the analyses presented here include
the large number of safety end-points assessed, the data-
set size (14 studies, 6241 patients) and the length of the
studies (up to 76 weeks). A limitation was the disparity
in exposure across the treatment groups due to differences
in population size and treatment duration, which was mit-
igated somewhat by the use of exposure-adjusted data.
Conclusions
In conclusion, this integrated safety analysis demonstrates
that the safety profile of FF is consistent with known ICS
class effects in patients with asthma, such as local steroid
effects, and once-daily FF 100 μg and FF 200 μg doses are
well tolerated in adult and adolescent patients with a
range of asthma severities. There was no evidence of corti-
sol suppression at the doses studied. It should be noted
that the safety data has been pooled from different studies
and that the individual studies were not designed to iden-
tify significant differences regarding specific AEs.Additional files
Additional file 1: Table S1. Summary of demographic characteristics
and treatment exposure by treatment group (DOCX 41 kb)
Additional file 2: Figure S1. Plot of pneumonia incidence per 1000
patient-years and 95% CI by treatment group (integrated clinical studies).
BD, twice daily; CI, confidence interval; FF, fluticasone furoate; FP, flutica-
sone propionate; OD, once daily. (TIF 465 kb)
Additional file 3: Figure S2. Plot of serious pneumonia incidence per
1000 patient-years and 95% CI by treatment group (integrated clinical
studies). BD, twice daily; CI, confidence interval; FF, fluticasone furoate; FP,
fluticasone propionate; OD, once daily. (TIF 427 kb)Abbreviations
AE: Adverse event; AESI: Adverse event of special interest; CI: Confidence
interval; FEV1: Forced expiratory volume in one second; FF: Fluticasone
furoate; FP: Fluticasone propionate; HPA: Hypothalamic-pituitary-adrenal;
HR: Hazard ratio; ICS: Inhaled corticosteroids; MedDRA: Medical dictionary for
regulatory activities; PEF: Peak expiratory flow; SAE: Serious adverse event
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